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Abstract 
Immune dysregulation during pregnancy may influence behavior and neurodevelopment 
in offspring, but few human studies have tested this hypothesis. Using structural equation 
modeling, we examined associations between maternal inflammatory markers at 28 weeks 
gestation and child neurodevelopmental outcomes at 20 months of age in a sample of 1,453 
mother-child pairs. We observed several associations between maternal inflammatory markers 
measured in the late second or early third trimester and child neurodevelopmental outcomes. The 
direction of association for some markers was unexpected. Further research is warranted to 
confirm and elucidate the exact nature of these findings. 
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1. Introduction 
 During pregnancy, a fundamental feature of the immune system is to regulate the balance 
between protection of both the mother and developing fetus against pathogens present in their 
environment, and maintaining tolerance of the fetal allograft (Aghaeepour et al., 2017). In 
normal pregnancy, each trimester is marked by changes in immunological functioning. In the 
first trimester Th1-type immunity is predominant, characterized by cell-mediated inflammatory 
reactions and production of pro-inflammatory responses (e.g., IL-1β, IL-2, IFN-γ, TNF-α) 
(Sargent et al., 2006; Wegmann et al., 1993). In the second and early-third trimesters, a shift is 
observed toward Th2-type immunity, characterized by B-cell activation and production of 
antibodies and anti-inflammatory responses (e.g., IL-4, IL-5, IL-10) (Sargent et al., 2006; 
Wegmann et al., 1993). During the mid- to late-third trimester, the renewed pro-inflammatory 
(Th1) state takes over to promote contraction of the uterus and prepare for delivery of the baby 
and placenta (Racicot et al., 2014). The Th1/Th2 ratio is commonly used to characterize 
dominating cytokine patterns, although this ratio may not fully capture variations in immune 
responses (Kidd, 2003). In addition to the Th1 and Th2 cytokines, chemokines, angiogenesis 
markers, and C-reactive protein (CRP) each play a role in the multifaceted and complex 
processes that comprise the immune system during pregnancy (Szarka et al., 2010). 
 Experimental animal research indicates that the maternal gestational immune response is 
important for successful pregnancy and positive birth and developmental outcomes, and this is 
hypothesized to also be true in humans (Chau et al., 2016). Experimental murine studies show 
that prenatal inflammation can cause both immediate and lasting changes in behavior and CNS 
structure and function in offspring, impairing working memory, spatial learning, locomotor 
activity, and startle reactivity (see Boksa, 2010, for a review). When looking at specific 
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inflammatory cells in pregnant rats at the beginning of the human equivalent of the third 
trimester, Gilmore and colleagues (2004) found that higher levels of the cytokine IL-6, which is 
considered to have both pro- and anti-inflammatory properties, and the pro-inflammatory 
cytokines IL-1β and TNF-α reduce the number of primary dendrites that develop and diminish 
the complexity of embryonic cortical neurons.  
Human research on the effects of maternal immune response on later child developmental 
outcomes is limited but suggests that maternal immune activation can hinder neurodevelopment. 
Higher levels of maternal mid-gestational IL-1, TNF-α, and IL-6 increase the risk of 
intraventricular hemorrhage and neonatal white matter damage (Dammann and Leviton, 1997), 
although the mechanisms that underlie this association are not well understood (Smith et al., 
2007). Studies have mostly examined maternal infections or autoimmune conditions rather than 
specific cytokines or other inflammatory markers, and studies have focused on autism spectrum 
disorders (ASD) and mental disorders rather than more subtle measures of neurodevelopment 
(Brown, 2012; Jiang et al., 2016). Nevertheless, most relevant to the current study, several case-
control studies have reported associations between specific prenatal cytokine and chemokine 
concentrations and ASD risk. Studies in which inflammatory markers were measured at early or 
mid-gestation reported an increased risk of ASD with increasing serum concentrations of IFN-γ, 
IL-2, IL-4, and IL-6 (Goines et al., 2011), MCP-1, IL-4, IL-10, TNF- α, and TNF-β (Abdallah et 
al., 2013, 2012), IFN-γ, IL-1α, and IL-6 (Jones et al., 2017), and C-reactive protein (CRP) 
(Brown et al., 2014). In contrast, a recent study reported an increased risk of ASD with lower 
maternal CRP markers (Zerbo et al., 2016), and mothers of children with ASD (without 
intellectual disability) or developmental delay had lower IL-8 and MCP-1 concentrations than 
controls (Jones et al., 2017). Thus, while psychoneuroimmunology studies suggest that the 
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prenatal immune system is linked to brain and nervous system development, potentially resulting 
in later behavioral and psychopathological outcomes, further research is needed to elucidate the 
exact nature of these complex relationships (O’Connor et al., 2014). 
 The Seychelles Child Development Study Nutrition Cohort 2 (SCDS NC2) is a large, 
well-characterized prospective birth cohort (N = 1535) from the Republic of Seychelles that was 
designed to evaluate whether prenatal exposure to methylmercury and nutrients from high fish 
consumption during pregnancy influences child development (Strain et al., 2015), and whether 
pro- and anti-inflammatory markers play a role in these associations. In this analysis, we 
examined complex maternal gestational cytokine profiles as well as chemokines, CRP, and 
markers of angiogenesis in relation to various developmental outcomes to further our 
understanding of the role of maternal immune dysregulation in neurodevelopment. We 
hypothesized that pro-inflammatory (Th1) markers would be adversely associated with 
developmental outcomes and anti-inflammatory (Th2) markers would be beneficially associated.  
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2. Methods 
2.1 Study Population 
SCDS NC2 has been described in detail elsewhere (Strain et al., 2015). In short, 1,535 
pregnant women were recruited from 2008 to 2011 during their first antenatal visit (from 14 
weeks gestation). Inclusion criteria for NC2 included being native Seychellois, being ≥16 years 
of age, having a singleton pregnancy, and having no obvious health concerns (Strain et al., 
2015). Children were tested for developmental outcomes at about 20 months of age. They were 
included in the current sample if they had available developmental assessment data and data 
from an assay of inflammatory markers in maternal serum at 28 weeks gestation, and relevant 
covariates (see Exclusions). The study was reviewed and approved by the Seychelles Ethics 
Board and the Research Subjects Review Board at the University of Rochester. 
2.2 Exclusions 
The following exclusion criteria were applied for the current study: birthweight <1500 g 
(n = 6), pre- or perinatal death (n = 20), maternal pre- or perinatal complications (n = 3), head 
trauma with loss of consciousness (n = 3), seizures (n = 10), disability (n = 1), and twin births (n 
= 34). An additional participant was also removed after withdrawing consent to participate in the 
study. Also, inflammatory markers vary throughout pregnancy (Sargent et al., 2006; Wegmann et 
al., 1993), thus two participants were removed because their serum samples were obtained at 
gestational ages (18 and 40 weeks) that varied substantially from the rest of the cohort (20 – 33 
weeks, interquartile range (IQR) 27 – 28 weeks). Finally, two mothers with unusually high 
values for most inflammatory markers measured here were excluded from all analyses. As such, 
our study population consisted of mothers and children without apparent clinical problems. The 
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total sample size after exclusions was 1408, corresponding to the number of participants with 
data for at least one inflammatory marker.    
2.3 Developmental assessment 
At around 20 months of age (mean 20 months (SD = 1.4), IQR = 20 – 21 months, range: 
15-32 months), children were examined by trained nurses using the following measures: (1) 
Bayley Scales of Infant Development II (BSID-II), a commonly used developmental test that 
yields two standard scores reflecting children’s current cognitive (MDI) and psychomotor skills 
(PDI); (2) MacArthur-Bates Communicative Development Inventory (CDI), a standardized 
parental survey that yields separate raw scores for Words Produced, Words Understood, and 
Total Gestures; and (3) the Infant Behavior Questionnaire – Revised (IBQ-R), which is a parent 
questionnaire that assesses child temperament. We used raw scores from the three IBQ-R 
subscales: surgency (a dimension of temperament in which a person tends towards extraversion, 
sociability and impulsivity), negative affect, and effortful control.  
2.4 Inflammatory Markers 
Non-fasting blood samples were collected at approximately 28 weeks of gestation (mean 
28 weeks (SD = 1.1)). Samples were collected by antecubital venipuncture into evacuated serum 
tubes. They were placed on water ice and allowed to sit for 30 minutes before being centrifuged 
at 2500 rpm for 15 minutes. Aliquots were shipped to Ulster at -80 °C and stored until analysis. 
Analysis of serum inflammatory markers took place approximately five years after sample 
collection, and were assayed via Meso Scale Discovery (MSD) multiplex assay. Freeze thaw 
cycles were avoided by using a fresh unthawed aliquot for each participant ID. This would 
minimize any effect of long-term storage on cytokine concentrations, as all samples were treated 
the same. 
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We selected a panel of inflammatory markers for assessment in maternal serum samples 
based on reported associations with methylmercury exposure and n-3 long-chain polyunsaturated 
fatty acid status (the original predictors of interest for developmental outcomes in the NC2 study) 
(Nyland et al., 2011b, 2011a), or because they are believed to play a role in fetal brain 
development (Smith et al., 2007). We quantified cytokines from the two major subsets of T 
helper (Th) cells, Th1 and Th2. Pro-inflammatory cytokines associated with cell-mediated 
reactions (Th1) included interleukin (IL)-1β, IL-2, interferon-gamma (IFN-γ), and tumor 
necrosis factor alpha (TNF-α). Anti-inflammatory cytokines associated with B-cell activation 
and antibody production (Th2) included IL-4, IL-5, and IL-10. IL-6, which has both pro- and 
anti-inflammatory roles (Diehl and Rincón, 2002), was also measured. Additional inflammatory 
markers included C-reactive protein (CRP); the chemokines monocyte chemoattractant protein 1 
(MCP-1) and thymus and activation regulated chemokine (TARC); and the angiogenesis markers 
soluble fms-like tyrosine kinase 1 (sFlt-1) and vascular endothelial growth factor D (VEGF-D). 
The individual biomarkers were analyzed as continuous variables measured in pg/mL, except 
CRP which was measured in mg/L. 
Values below the lower limit of detection (LLOD) for each marker were imputed as 
LLOD/2 (see Table 2 for LLOD values, percent detected for each analyte, and inter- and intra-
assay coefficients of variation). Two markers had a substantial amount (> 20%) of undetectable 
values: IL-2 (LLOD: 0.09 pg/mL; 36.1% detected) and IL-4 (LLOD: 0.02 pg/mL; 35.5% 
detected). Excluding IL-2 and IL-4 did little to impact the relationships with developmental 
outcomes, therefore, we kept these markers in the analyses. 
2.5 Covariates 
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As in Strain et al. (2015), our models adjusted for the following variables thought to 
impact child development as covariates in the regression models: maternal age, child age at 
testing (in months), child sex, Hollingshead socioeconomic status (SES; possible range 8 – 66, 
with higher scores indicating higher SES), and number of parents living with the child (0 – 2). 
Maternal age, child age at testing (in months), and Hollingshead socioeconomic status were 
treated as continuous variables.   
2.6 Statistical Analyses 
First, we calculated measures of central tendency and variance to describe demographics, 
developmental characteristics, and inflammatory markers in mothers and children (see Tables 1 
and 2). Subsequently, we examined the presence of influential points (Cook’s distances larger 
than 0.50) or statistical outliers (standardized residuals in excess of ± 3) in each model as defined 
previously (van Wijngaarden et al., 2013). No influential points were identified, but a small 
number of statistical outliers were identified (ranging from 0 to 13 depending on the model). 
Models were run with and without these values. The interpretation of results with and without 
outliers remained the same (data not shown), and thus we present the results here using the full 
dataset including outliers.  
Then, to identify whether there was any natural clustering among the inflammatory 
marker variables, an exploratory factor analysis with geomin oblique rotation was conducted 
with Mplus, version 8 (Muthén and Muthén, 1998-2017). Full-information maximum likelihood 
(FIML) with robust standard errors was used as the estimator to address missing inflammatory 
marker data (N = 1416). This is considered the ideal approach when conducting analyses with 
incomplete and nonnormal data (Newman, 2014; Yuan, 2009). The fit of each model was 
examined via the magnitude and p values of loadings, and model fit statistics such as the Root 
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Mean Square Error of Approximation (RMSEA), Comparative Fit Index (CFI), and Bayesian 
Information Criterion (BIC). Variables with non-significant rotated factor loadings were 
removed and models re-run until all remaining factor loadings were significant and model fit 
statistics were satisfactory. It was hypothesized that two factors would emerge, representing pro- 
or anti-inflammatory activity. 
The identified factors were then modeled as latent factors in regression models predicting 
each developmental outcome at 20 months, after adjustment for maternal age, child age at 
testing, child sex, Hollingshead socioeconomic status, and number of parents living with the 
child. Then, additional regression models were run with the 13 individual biomarkers (IL-1β, IL-
2, IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-10, MCP-1, TARC, sFlt-1, VEGF-D, CRP) predicting each 
developmental outcome at 20 months (BSID-II PDI and MDI; MacArthur-Bates CDI Words 
Produced, Words Understood, and Total Gestures; and IBQ-R Surgency, Negative Affect, and 
Effortful Control), adjusting for the same covariates as before. FIML with robust standard errors 
was again used as the estimator (N = 1453). We confirmed that collinearity (e.g. variance 
inflation factors >10, correlations >0.9) between the inflammatory markers was not an issue in 
these regression models. Moreover, in secondary analyses we used categorical inflammatory 
marker variables (with categories based on bands of multiples of 1 SD above and below the 
mean for each variable, using the lowest category as the reference group) to further examine 
dose-response patterns and determine the consistency of results. Interpretation of the findings 
was not materially different to that using the continuous inflammatory marker variables, and 
categorical results were therefore not further presented. Analyses were conducted with Mplus, 
version 8 (Muthén and Muthén, 1998-2017).  
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3. Results 
Summary statistics for the participants and variables included in the study are presented 
in Tables 1 and 2. Mothers were on average about 27 years old. The sample included more boys 
than girls (52.1%). Most children (1008, 73.3%) reportedly lived with both parents, whereas 352 
(25.6%) lived in a one-parent household, and 15 (1.1%) did not live with either parent. The 
average Hollingshead SES was near the midpoint of the scale, with scores ranging from very low 
to very high SES.  
Exploratory factor analysis with geomin oblique rotation was conducted to determine 
whether there were distinct clusters, or factors, that arise within the group of inflammatory 
markers, reflective of the complex functions and interrelations within the immune system. It was 
hypothesized that two factors would emerge, representing pro- or anti-inflammatory activity. 
Full-information maximum likelihood (FIML) with robust standard errors was used as the 
estimator for analyses conducted in Mplus. In line with our hypothesis, the model with two 
extracted factors was the best fit to the data. Contrary to hypotheses, however, these factors were 
not strictly pro- and anti-inflammatory in nature (see Table 3 for a summary of the factor 
analysis results). The mostly pro-inflammatory factor was comprised of IL-1β, CRP, IL-6, MCP-
1, and sFlt-1, and the mostly anti-inflammatory factor was comprised of IL-4, IL-5, IL-10, IL-2, 
IFN-γ, and TNF-α. In the initial run of the two-factor model, TARC and VEGF-D were not 
loading on either factor and thus were removed for the final model run. The final two-factor 
model had an RMSEA of .04 (90% CI: .03 - .05) and CFI of .78, indicating acceptable model fit. 
The p value representing whether there is a statistically significant improvement in fit for the 
model with one more factor indicated that the two-factor model was a better fit than the one-
factor model (p < .001).  This test also indicated that the three-factor model was a better fit than 
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the two-factor model (p < .001), but the three-factor model had a slightly higher BIC value 
(44071.51 versus 44061.70 for the two-factor model; lower BIC is preferred), and the third factor 
was only comprised of two inflammatory markers (IFN-γ and CRP) that were cross-loading on 
the anti- and pro-inflammatory factors, respectively. Thus, the two-factor model was retained for 
further analyses. 
The two factors identified from the exploratory factor analysis were then modeled as 
latent factors in structural equation models predicting each developmental outcome at 20 months, 
after adjustment for maternal age, child age at testing, child sex, Hollingshead socioeconomic 
status, and number of parents living with the child (see Table 4). The latent pro- and anti-
inflammatory factors were largely unrelated to developmental outcomes at 20 months, with the 
exception of a modest association between the anti-inflammatory factor and psychomotor 
development (PDI) scores (B [95% CI] = -2.66 [-5.07, -0.25]; p = .03), such that an overall 
increase in maternal anti-inflammatory activity at 28 weeks gestation was modestly associated 
with worse psychomotor development outcomes at 20 months.  
Then, additional regression models were run with all continuous inflammatory marker 
variables together in a path model predicting each developmental outcome at 20 months, 
adjusting for the same covariates as before (see Figures 1, 2, and 3). Across all models, increased 
TARC was significantly associated with better psychomotor development (PDI; B [95% CI] = 
0.44 [0.22, 0.66]; p < .001), more use of gestural communication (B [95% CI] = 0.61 [0.33, 
0.89]; p < .001), increased negative affect (B [95% CI] = 0.03 [0.01, 0.06]; p = .005), and better 
effortful control (B [95% CI] = 0.05 [0.02, 0.07]; p < .001); increased VEGF-D was significantly 
associated with better psychomotor development (B [95% CI] = 0.37 [0.08, 0.66]; p = .01), better 
receptive language skills (B [95% CI] = 3.82 [1.10, 6.54]; p = .006), and more use of gestural 
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communication (B [95% CI] = 0.37 [0.14, 0.60]; p = .002); increased IL-1β was associated with 
decreased negative affect (B [95% CI] = -0.10 [-0.17, -0.03]; p = .004) and better effortful 
control (B [95% CI] = 0.06 [0.004, 0.11]; p = .036); increased IL-2 was significantly associated 
with worse psychomotor development (B [95% CI] = -0.96 [-1.85, -0.07]; p = .03); increased IL-
10 was associated with less use of gestural communication (B [95% CI] = -0.18 [-0.31, -0.04]; p 
= .01); and increased sFlt-1 was associated with increased negative affect (B [95% CI] = 0.06 
[0.01, 0.10]; p = .009). No other inflammatory marker significantly predicted 
neurodevelopmental outcomes at 20 months.  
As previously reported (Strain et al., 2015), associations between child, maternal, and 
familial covariates and developmental outcomes, when present, were in the expected directions. 
4. Comments 
We studied the association of maternal markers of inflammation with children’s 
neurodevelopmental scores and hypothesized pro-inflammatory markers to be associated with 
poorer child performance and anti-inflammatory markers to be associated with better 
performance on the developmental assessments at 20 months. We found significant beneficial 
associations for pro-inflammatory markers TARC and IL-1β, and pro-lymphangiogenic VEGF-
D, and adverse associations for pro-inflammatory IL-2, anti-inflammatory IL-10, and anti-
angiogenic sFlt-1. In addition, the mostly anti-inflammatory factor identified by the exploratory 
factor analysis (comprised of IL-2, IL-4, IL-5, IL-10, IFN-γ, and TNF-α) was adversely 
associated with psychomotor development. Thus, few of the significant associations we found 
were in the expected directions.  
IL-2 and sFlt-1 each demonstrated an adverse association, with psychomotor 
development and increased negative affect, respectively. In a small case-control study, increased 
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IL-2 concentrations were associated with an increased risk of autism spectrum disorder (Goines 
et al., 2011), which itself is associated with motor deficits (Bo et al., 2016). In addition, another 
study found that higher levels of sFlt-1 during mid-pregnancy are associated with poorer 
neonatal outcomes (Masoura et al., 2014), The rest of the significant inflammatory markers, 
however, demonstrated unexpected associations with child developmental outcomes. IL-1β had 
unexpected beneficial associations with reduced negative affect and better effortful control, but 
in concentrations reflecting physiological and not inflammatory amounts, IL-1β has been found 
to have neuroprotective effects and is important for normal brain function (Hewett et al., 2015).  
Despite the statistically significant findings in the current study, these associations were 
modest in magnitude and no clear patterns of associations emerged. Thus, the results of this 
study do not support a strong link between the maternal gestational immune markers assayed and 
child neurodevelopmental outcomes. While the unexpected directions of some of our 
associations currently have no clear biological explanation and may simply be false positives, the 
maternal immune response during pregnancy is complex and little is known about its relationship 
with developmental outcomes in children. Therefore, our associations necessitate confirmation 
and further clarification.  
This study has important strengths, in particular its use of a well-controlled, large 
prospective birth cohort of children, the relatively large panel of inflammatory markers, and the 
use of humans as opposed to animals, all of which are rare in the study of maternal immune 
activation and child outcomes. Nevertheless, our study also has several limitations, which may 
have limited our ability to observe clear patterns of association. Levels of inflammatory markers 
fluctuate throughout pregnancy (Sargent et al., 2006; Wegmann et al., 1993). Concentrations at 
28 weeks gestation could vary from concentrations at other time points that were not measured in 
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the current study but could be more strongly associated with developmental endpoints. Although 
we selected a broad panel of inflammatory markers, there are others that we did not study.  
Furthermore, the current study lacked information that could have aided in the interpretation of 
our results or affected levels of inflammatory markers and child developmental outcomes, 
including data on whether the mothers had specific inflammatory or autoimmune conditions, 
whether they were exposed to certain infectious agents during pregnancy, maternal pregnancy 
BMI, breastfeeding, and the health of the child. However, we excluded mothers and children 
with certain clinical conditions. Moreover, measurable levels of inflammatory markers can be 
affected by the time samples spent in storage (in this study, approximately five years), possibly 
due to cytokine degradation (de Jager et al., 2009; Parkitny et al., 2013; Zhou et al., 2010). 
However, all samples in the current study underwent the same conditions of freezing, storage, 
and thawing, and we would not expect the impact of storage on inflammatory marker 
concentrations to vary based on neurodevelopment outcomes or other variables in the model. 
Additionally, blood draws generally took place in the morning, but record of the specific time at 
which each blood draw occurred is only available for 406 participants. The current study was 
therefore unable to account for any potential diurnal rhythms in the inflammatory markers; 
however, of the 406 blood draws, 364 (90%) took place before noon, and 42 (10%) took place 
between noon and 3pm, so we would not expect diurnal rhythms to vary significantly nor be 
associated with any of the developmental outcomes. Finally, inherent in any study of 
developmental outcomes in infants, the dependent variables are less sensitive and specific than 
measures of child development at older ages (Mahaffey, 1998); and the precision of the 
independent biomarkers is in sharp contrast to these endpoint measures. Further research at older 
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ages will be necessary to capture more robust developmental endpoints and to clarify the ideal 
balance of pro- versus anti-inflammatory cytokines and chemokines throughout pregnancy. 
In conclusion, while several associations were observed between inflammatory markers 
measured around 28 weeks of gestation and neurodevelopmental outcomes at 20 months of age, 
the direction of these associations was not consistent. Our findings could reflect the true absence 
of associations in a relatively healthy population of mothers and children, or be the result of 
methodological limitations preventing us from detecting subtle associations. Further study is 
required using measurements of maternal inflammatory markers at various points throughout 
gestation to examine whether differences in absolute amounts or trajectories of inflammatory 
markers are associated with child neurodevelopmental outcomes.  
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Table 1 
Summary statistics for maternal inflammatory markers at 28 weeks gestation, infant developmental 
outcomes at 20 months of age, and model covariates 
 n M (SD) or n (%) Minimum Median Maximum 
Developmental Outcomes      
BSID-II MDI, scaled score 1385 87.59 (10.70) 49 88 118 
BSID-II PDI, scaled score 1383 96.71 (10.54) 49 97 136 
CDI Vocabulary Produced 1411 122.47 (88.19) 0 109 395 
CDI Vocabulary Understood 1411 233.48 (91.39) 0 228 396 
CDI Total Gestures 1411 46.55 (8.30) 2 47 63 
IBQ-R Surgency 1410 5.39 (0.57) 2.15 5.46 7 
IBQ-R Negative Affect 1410 4.12 (1.00) 1 4.17 7 
IBQ-R Effortful Control 1410 5.19 (0.55) 1 5.25 7 
Covariates      
Child sex (male or female) 1448 757 (52.3%) males    
Mother’s age at enrollment 1451 26.86 (6.30) 16.03 25.89 46.56 
Child’s age at visit (months) 1411 20.27 (1.44) 15 20 32 
Number of parents living with the 
child 1411 
1030 (73.8%) 2 
parents 1  2 
Hollingshead SES 1411 31.97 (10.40) 11 31.50 63 
Note. Descriptive analyses presented are using raw, untransformed variables. BSID-II: Bayley Scales of 
Infant Development II; MDI: Mental Development Index; PDI: Psychomotor Developmental Index; CDI: 
MacArthur-Bates Communicative Development Inventory; IBQ-R: Infant Behavior Questionnaire-
Revised. SES: socioeconomic status. 
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Table 2 
      
Summary statistics and coefficients of variation for maternal inflammatory markers at 28 
weeks gestation 
Inflammatory 
Marker n M (SD) 
LLODc  
(% detected) 
Inter-Assay 
CV (%) 
Intra-Assay 
CV (%) 
IL-1β 1408 0.32 (0.62) 0.04 (82.6%) 44.38 <26 
IL-2 1408 0.27 (0.59) 0.09 (36.1%) 25.46 <35 
IFN-γ 1408 5.59 (22.05) 0.20 (84.4%) 22.29 <20 
TNF-α 1408 7.18 (7.18) 0.04 (100%) 16.14 <22 
IL-4 1408 0.14 (0.55) 0.02 (35.5%) 15.28 <30 
IL-5 1408 1.34 (2.19) 0.22 (100%) 11.87 <17 
IL-10 1408 1.55 (7.22) 0.03 (90.6%) 16.48 <20 
IL-6 1408 1.01 (1.62) 0.06 (88.7%) 22.96 <28 
MCP-1 1408 74.89 (88.67) 0.09 (100%) 7.72 <20 
TARC 1408 100.51 (138.75) 0.22 (100%) 22.2 <15 
sFlt-1 1408 2069.69 (1378.88) 0.56 (100%) 12.54 <22 
VEGF-D 1408 738.58 (372.06) 2.53 (100%) 17.41 <15 
CRP 1379 3.52 (2.71) 1 (98.9%) 3.5 <1.8 
Note. Serum biomarkers measured in pg/mL, except CRP which was measured in mg/L. 
LLOD: lower limit of detection. CV: coefficient of variation. 
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Table 3 
 
Results of exploratory factor analysis with continuous inflammatory 
marker variables at 28 weeks gestation (N = 1416) 
Biomarker 
Geomin Rotated Standardized Factor Loadings 
Factor 1  
(Pro-Inflammatory) 
Factor 2  
(Anti-Inflammatory) 
IL-1β .40  
IL-6 .87  
MCP-1 .47  
sFlt-1 .22  
CRP .22  
IL-2  .56 
IFN-γ  .26 
TNF-α  .41 
IL-4  .39 
IL-5  .28 
IL-10  .13 
Note. All loadings are geomin rotated standardized factor loadings 
significant at the p < .05 level. 
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Table 4 
 
Pro-inflammatory versus anti-inflammatory latent factorsa, comprised of continuous inflammatory markers at 28 weeks 
gestation, predicting developmental outcomes at 20 months of age (N = 1453) 
Developmental Outcome Latent Factor B [95% CI]b 
Bayley Scales of Infant Development-II Mental Development Index Pro-Inflammatory 1.23 [-1.31, 3.78] 
  Anti-Inflammatory -1.94 [-4.32, 0.44] 
 Psychomotor Development Index Pro-Inflammatory -0.43 [-3.16, 2.30] 
  Anti-Inflammatory -2.66 [-5.07, -0.25]* 
    
MacArthur-Bates CDI Vocabulary Produced Pro-Inflammatory 10.49 [-12.86, 33.83] 
  Anti-Inflammatory -12.15 [-33.98, 9.69] 
 Vocabulary Understood Pro-Inflammatory -0.05 [-19.67, 19.58] 
  Anti-Inflammatory -19.36 [-47.66, 8.93] 
 Total Gestures Pro-Inflammatory 0.40 [-1.46, 2.26] 
  Anti-Inflammatory -0.83 [-3.72, 2.06] 
    
Infant Behavior Questionnaire - Revised Surgency Pro-Inflammatory 0.02 [-0.16, 0.20] 
  Anti-Inflammatory -0.08 [-0.29, 0.13] 
 Negative Affect Pro-Inflammatory 0.06 [-0.19, 0.31] 
  Anti-Inflammatory -0.16 [-0.46, 0.15] 
 Effortful Control Pro-Inflammatory 0.03 [-0.15, 0.20] 
  Anti-Inflammatory 0.06 [-0.17, 0.29] 
a Pro-inflammatory latent factor: IL-1β, IL-6, MCP-1, sFlt-1, CRP 
Anti-inflammatory latent factor: IL-2, IFN-γ, TNF-α, IL-4, IL-5, IL-10 
b Estimated unstandardized regression coefficients and corresponding 95% confidence intervals are shown, after 
adjustment for the following covariates: maternal age at enrollment, child age at testing, child sex, number of parents 
living with the child, and Hollingshead socioeconomic status. 
MacArthur-Bates CDI: Communicative Development Inventories, Words & Gestures 
* p < .05. 
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